Drug Profile
Research programme: triple reuptake inhibitors - Prexa
Alternative Names: PRX-12251; PRX-12255Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Prexa Pharmaceuticals
- Class Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Depressive disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Depressive disorders in USA (PO, Controlled release)
- 12 Jan 2011 Triple reuptake inhibitors are available for licensing as of 12 Jan 2011. http://www.prexapharmaceuticals.com/
- 07 Dec 2010 Preclinical trials in Depressive disorders in USA (PO)